Hokkaido Cancer Society
Scientific academy / society / association
Location:
Sapporo,
Japan (JP)
Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al.
Conference contribution
HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022)
Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al.
Conference contribution
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC (2021)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kummel S, Bergh J, et al.
Conference contribution